tlx250
telix
['renal,(-adrenal)', 'rcc,(-irccs),(-srcc),(-urcc)', 'telix pharma']
today at #asco22, dr. darren feldman from presents the #starlite 2 study of telix s #renalcancer therapy candidate tlx250. this study is assessing the efficacy of targeted radiation in combination with immunotherapy for clear cell renal cell carcinoma #ccrcc. 
Telix is a "theranostics" company developing a pipeline of late-stage oncology assets in prostate cancer, renal cancer and glioblastoma. #SeeItTreatIt